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Abstract
Background: Conservative treatment remains the standard of care for treating mild to moderate
carpal tunnel syndrome despite a small number of well-controlled studies and limited objective
evidence to support current treatment options. There is an increasing interest in the usefulness of
wrist magnetic resonance imaging could play in predicting who will benefit for various treatments.
Method and design: Two hundred patients with mild to moderate symptoms will be recruited
over 3 1/2 years from neurological surgery, primary care, electrodiagnostic clinics. We will exclude
patients with clinical or electrodiagnostic evidence of denervation or thenar muscle atrophy.
We will randomly assign patients to either a well-defined conservative care protocol or surgery.
The conservative care treatment will include visits with a hand therapist, exercises, a self-care
booklet, work modification/ activity restriction, B6 therapy, ultrasound and possible steroid
injections. The surgical care would be left up to the surgeon (endoscopic vs. open) with usual and
customary follow-up. All patients will receive a wrist MRI at baseline.
Patients will be contacted at 3, 6, 9 and 12 months after randomization to complete the Carpal
Tunnel Syndrome Assessment Questionnaire (CTSAQ). In addition, we will compare disability
(activity and work days lost) and general well being as measured by the SF-36 version II. We will
control for demographics and use psychological measures (SCL-90 somatization and depression
scales) as well as EDS and MRI predictors of outcomes.
Discussion: We have designed a randomized controlled trial which will assess the effectiveness of
surgery for patients with mild to moderate carpal tunnel syndrome. An important secondary goal
is to study the ability of MRI to predict patient outcomes.
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Background
Carpal tunnel syndrome (CTS) is the most common
peripheral nerve entrapment syndrome, with an annual
incidence of 50–150 cases/100,000. It is an important
cause of workplace morbidity [1] with approximately
30,000 cases of CTS resulting in days lost from work in
1996 (BLS US Department of Labor 1998; [2]). Typical
symptoms include paresathesia, pain, and weakness in a
median motor nerve distribution, which are often worse
at night [3,4]. Although frequently idiopathic, CTS may be
associated with diabetes, thyroid disorders, pregnancy,
renal dialysis, and other conditions [5].
A Cochrane literature review [6] for randomized trials that
compared surgical to non-surgical treatment of CTS
included only one article [7]. This study demonstrated sig-
nificant clinical improvement in electromyography and
symptoms reported at 1 year for surgical release over
splinting with a cohort of 22 women. More recently, Ger-
ritsen et al, published a second randomized study of sur-
gical release versus splinting in 176 patients with
moderate carpal tunnel syndrome, defined by clinical and
electrophysiological testing [8,9]. Surgical patients had
greater improvement in the number of nights waking up
due to symptoms, and severity of symptoms, as well as on
a general improvement scale. However, the evidence is
less clear for patients with a shorter duration of symptoms
or the use of conservative therapies other than splinting,
such as physical therapy and ultrasound [9,10].
Although there is generally a lack of rigorous scientific
support for non-surgical treatments for CTS [2], there is
limited evidence of benefit for certain interventions.
Common conservative treatments for CTS include wrist
splints, hand therapy, non-steroidal anti-inflammatory
drugs (NSAIDs), and corticosteroid injection into the car-
pal tunnel [11-26]. Garfinkel [15] reported that yoga hand
exercises resulted in improved Phalen sign compared with
splints. Rozmaryn [14] reported that nerve and tendon
gliding exercises coupled with traditional conservative
care may reduce the need for surgery. Little evidence exists
to support the use of NSAIDs for treating CTS. Celiker et
al [16] found that corticosteroid injection into the carpal
tunnel was superior to NSAID therapy and Davis and col-
leagues [12,13] reported that ibuprofen combined with
nocturnal splints did not improve outcomes more than
chiropractic manipulation [15,17-19]. Local injection of
corticosteroid into the carpal tunnel improves short-term
clinical outcomes, as compared with oral corticosteroids,
intramuscular corticosteroid injections, NSAIDS, or
splints alone. [16,20-23]. Herskovitz and colleagues [24]
demonstrated a short term improvement in global symp-
tom scores for CTS with oral corticosteroid compared to
placebo, but Chang could not find a dose response
[25,26]. While these finding suggest some potential ther-
apeutic benefits, none of these therapies either alone or in
combination have been rigorously compared to surgery.
Although not commonly used, Ebenbichler [27] found
that focused ultrasound significantly improved symptom
and electrophysiological outcomes compared with sham
ultrasound. Vitamin B-6 has also been suggested as a treat-
ment for CTS, [28-32] but two studies [33] failed to dem-
onstrate improvement in outcome.
Diagnostic criteria for grading CTS severity as "mild" and
"moderate" are not well established. Electrodiagnostic
studies (EDS) do not correlate well with clinical severity
and have not been shown to accurately predict outcomes
for patients with mild to moderate CTS [34-42].
We designed a randomized clinical trial to compare surgi-
cal release to non-surgical treatment for patients with
mild to moderate CTS. We will examine the association
between outcome, as measured by symptoms and func-
tional status, and baseline variables such as symptoms,
function, occupational risk factors, EDS measures, demo-
graphics, signs and symptoms, and prior treatments. Our
primary endpoint is at 12 months.
In addition, our study will evaluate the ability of high res-
olution magnetic resonance imaging (MRI) of the wrist to
predict who will benefit from surgical release. MRI has the
potential to offer new insight into the diagnosis and man-
agement of patients with hand and wrist neurological
symptoms. Unlike electrodiagnostic studies, MRI directly
visualizes the median nerve and can detect abnormalities
of both configuration (nerve compression) as well as sig-
nal (indicating intraneural edema and demyelination)
[43-46]. Either or both of these findings have the poten-
tial to be better predictors of patient outcomes than elec-
trodiagnostic studies.
Finally, we will gather utilization data for each arm of the
study to test the hypothesis that the incremental cost-
effectiveness ratio of surgery falls below conventional
cost-effectiveness thresholds.
Methods/design
We have designed a multi-center, randomized trial com-
paring surgical release to a multi-component, non-surgi-
cal therapy. The study protocol was approved by the
University of Washington Human Subjects Division and
all participants provide written informed consent.
The two major goals of this study are to determine: 1) if
surgery compared with conservative therapy benefits
patients with mild or moderate carpal tunnel syndrome,
and, 2) if high resolution magnetic resonance imaging
(MRI) of the median nerve can identify patients for whomBMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
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early surgery might be more efficacious than conservative
therapy.
Patients with mild to moderate CTS are recruited from six
participating sites in the Puget Sound region of Washing-
ton State: the University of Washington (UW) affiliated
practice sites (University of Washington Medical Center,
UW Physicians Network, Harborview Medical Center,
Puget Sound VA Health Care System), Virginia Mason
Medical Center (Seattle), the Seattle Hand Surgery (affili-
ated with Swedish Hospital in Seattle), Proliance Sur-
geons (affiliated with Overlake and Evergreen Hospitals),
and Management Services Organization of Washington in
Tacoma. We recruit patients within the primary care clin-
ics as well as the specialty referral clinics that treat patients
with carpal tunnel syndrome. These clinics include neuro-
logical surgery, neurology, orthopedic surgery, and physi-
cal medicine and rehabilitation. Additionally, we identify
potential subjects in the electrophysiology laboratories at
each of our participating sites.
Prior to study participation, patients are required to have
a physician confirmation of suspected CTS and to obtain
an EDS with or without an electromyeogram (EMG). We
define mild to moderate carpal tunnel syndrome based on
electrodiagnostic studies (EDS) and clinical findings. Spe-
cifically, patients are eligible for the study if EDS demon-
strates any one of the following: (1) wrist median motor
nerve conduction latency greater than or equal to > = 4.4
milliseconds (ms), (2) a 10 cm (thumb to wrist) median
to radial sensory nerve ratio difference of > 0.5 ms, (3) an
8 cm mid-palm median to ulnar sensory nerve difference
> 0.3 ms, (4) a 14 cm (digit four to wrist) median to ulnar
difference of > 0.4 ms, or (5) a combined sensory index
[47,48]  ≥ 1.0 ms. Patients with normal EDS findings
could still qualify for the study if they reported hand
symptoms at night that awakened them, a positive flick
test, and a "classic", "probable" or "possible" evaluation
of a hand diagram. [49,50]
Other study inclusion criteria are: age 18 years or older, no
previous hand or wrist surgery on the study hand, no pre-
vious carpal tunnel release on the contralateral hand in
the previous 6 months, symptoms in at least two digits in
a median motor nerve pattern, able and willing to answer
research questionnaires in English, and classification
Table 1: Eligibility Criteria
Inclusion Exclusion
Symptoms in at least two digits on one hand (to include thumb, index, middle, or ring finger.) Wrist or hand surgery within last 6 months
Hand/ wrist symptoms >1 week Previous CTS release on study hand
Expect to stay in area for 1 year. Moderate to severe arthritis involving hand or 
wrist
Willing and able to complete phone interviews Known tumor, mass, or deformity in the hand 
or wrist
Over age 18 History of severe trauma to the wrist.
Able to complete questionnaires in English Pregnant or lactating
Any one of these EDS findings Motor: Median motor latency (wrist) > = 4.4 
ms
Median Motor amplitude <= 3.8 mV
Sensory: median-radial (10 cm thumb to wrist) 
difference >0.5 ms
EMG (if done) evidence of denervation
Sensory: Midpalm median-ulnar (8 cm) 
difference >0.3 ms
Evidence of diffuse peripheral neuropathy.
Sensory: Median-ulnar (14 cm digit IV to wrist) 
difference >0.4 ms
Thenar atrophy
Sensory: Combined Sensory index > = 1.0 ms
(With normal EDS) Night pain that wakes 
patient AND Positive flick test
Classic, probable, or possible hand pain diagram.
Two consecutive weeks of standard (non-surgical) treatment for CTS, including a trial of wrist 
splints.
Lack of improvement with conservative 
treatment documented by at least one of the 
following:
Improvement less than 0.75 in the CTSAQ 
functional?
Unable to achieve "satisfactory" level of work
Patient defined symptoms as being "same" or 
"worse" over the last two weeks.
Willing to schedule surgery within one week of randomization.BMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
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using the hand diagrams as at least "possible CTS"[49,50].
Exclusion criteria are prior CTS release on the involved
hand; diffuse peripheral neuropathy, any known mass,
tumor or deformity; any history of severe trauma to the
wrist (such as fracture); a deformity of the study hand; and
pregnant or lactating (table 1).
Patients with evidence of severe CTS on EDS, EMG, or
clinical findings are excluded from the study. Severe CTS
is defined as a median motor amplitude of ≤ 3.8 mV, EMG
evidence of denervation, or thenar atrophy.
Study participants are required to have not improved after
a minimum of two weeks of standard non-surgical treat-
ment (typically, wrist splints and NSAIDs) and be willing
to schedule surgery within one week if randomized to the
surgical arm of the trial. Lack of improvement with con-
servative care is defined by any of the following: (1) < 0.75
point improvement [51] on the Carpal Tunnel Syndrome
Assessment Questionnaire (see primary outcome meas-
ures), (2) self-reported inability to achieve a "satisfactory"
level of work due to hand or wrist problems, or (3) self-
report of symptoms as "same" or "worse" since they
started conservative therapy.
For patients with bilateral CTS, we designate a "study
hand" based on the following priorities: 1) most severe
according to patient reporting, 2) most severe based on
electrodiagnostic reports, and 3) the dominant hand.
We use a 50/50 computer-generated block randomiza-
tion, stratified by enrollment site. The block size is ran-
domly varied between 4 and 12 to reduce the potential for
clinicians or research staff to predict treatment allocation.
The treatment assignment is centrally administered and
concealed in consecutively numbered opaque envelopes.
Patients are randomized to receive either a surgical release
of the median nerve or a package of multiple, non-surgical
treatments tailored for individual patients. For those ran-
domized to surgery, we attempt to schedule the surgery
within two weeks of allocation or as soon as possible. Sur-
gery is performed by a board-certified neurological sur-
geon or orthopedic surgeon. Either open or endoscopic
surgery can be performed, depending on the surgeon's
preference. Surgical patients receive clinical follow-up just
as they would if not in the study. Typically, this includes a
follow-up visit within one week for wound and suture
management and several post-operative follow-up visits
with a hand therapist to perform median nerve and ten-
don gliding exercises.
We created expert focus groups and reviewed the relevant
body of literature to develop the non-surgical treatment
arm of study. Our focus group included experts in ortho-
pedics, neurosurgery, physical medicine and rehabilita-
tion, hand therapy, biostatistics, health services,
behavioral science, and health economics.
The non-surgical treatment is directed by a hand, occupa-
tional, or physical therapist and includes a minimum of
three visits, separated by 6 weeks each. At the first visit,
each patient receives an educational booklet, a prescrip-
tion for NSAIDs (if they have not previously tried them),
and specific exercises for their hand. The educational
booklet details the hand exercises, describes the causes of
carpal tunnel syndrome, and lists resources for obtaining
additional information. Work and activity modifications
are prescribed at the discretion of the hand therapist and
additional hand therapy visits are prescribed as needed.
Patients allocated to the non-surgical arm who have
already undergone extensive physical therapy can opt to
get ultrasound treatment immediately (see below).
Patients in the non-surgical arm return six weeks after the
randomization for a study visit. If a patient reports
improvement, no changes to their therapy are made. For
patients who do not improve, we offer oral vitamin B-6
supplements (100 mg per day) and ultrasound in addi-
tion to the existing therapy regimen. The ultrasound regi-
men used in this study consists of up to 12 sessions per
week (for 6 weeks) of focused ultrasound at 1 Mhz, 1.0 W/
sqr cm2, in pulsed mode 1:4, and 15-minutes each. Three
months after randomization, patients return for the final
non-surgical evaluation. If improved, they are instructed
in a self-care maintenance program and advised to return
to their provider if their symptoms worsen. If symptoms
are not improved, patients are referred to a study surgeon
for evaluation for crossover to receive surgery or corticos-
teroid injection.
Outcomes measures are collected for patients in person at
baseline and via telephone interviews at 3, 6, 9, and 12
months after randomization. Although it is impossible to
blind providers and patients to the treatment the assign-
ment, the telephone interviewer is blinded to study partic-
ipants' treatment assignment.
The functional status scale of the Carpal Tunnel Syndrome
Assessment Questionnaire (CTSAQ) is the primary out-
come measure. The CTSAQ is a self-report CTS functional
status and symptom severity questionnaire with estab-
lished validity, reliability and responsiveness [52,53]. The
functional status scale assesses ability to perform eight
common tasks involving the hands. The symptom severity
scale consists of eleven items assessing symptoms of pain,
numbness, and weakness at night and during the day.
Each question is answered on a scale of 1 to 5 and the
scales are scored by taking the mean of the responses, with
a higher score indicating greater severity.BMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
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The SF-36 Health Survey version 2 (QualityMetics Inc.,
Ware) has been used to assess general health status in
samples of patients with a variety of diseases, including
CTS [54]. It consists of eight domains (general health,
physical functioning, role limitations due to physical
problems, role limitations due to emotional problems,
bodily pain, social function, mental health, and vitality)
scored on a scale of 0 (worst health) to 100 (ideal health).
We will compare the two groups on each scale as well as
the physical and mental summary scores. The generic
nature of the instrument allows comparison across health
conditions.
Study participants also complete the Symptom Check List
SCL-90 12-item Somatization and 13-item Depression
scales [55-57]. Participants respond to each question
using a 5-point scale ranging from "not at all" to
"extremely". Higher scores indicate greater somatization/
depressive symptom severity.
The 13-item Pain Catastrophizing Scale is used as both a
predictor and a secondary outcome. A substantial volume
of research had consistently found substantial associa-
tions between pain-related catastrophizing and pain-
related disability [58-62]. We are interested in learning
whether pain-related catastrophizing is a risk factor for
poor outcomes in patients with CTS.
In addition to the outcome measures, we obtain informa-
tion on several other variables at baseline. This includes
information on demographics, occupational risk factors,
medical co-morbidity, hand pain history, work status, and
litigation/compensation issues. The first three items of the
Alcohol Use Disorders Identification Test (AUDIT) are
administered to assess the frequency of alcohol use,
amount of alcohol consumption, and binge drinking [63-
65].
We are also collecting information on the costs of care fol-
lowing enrollment. We aim to estimate the cost to health
purchasers and society based on billing and medical
records, and a detailed resource use questionnaire (RUQ)
at 3, 6, 9, and 12 months post-enrollment.
We attempted to either measure or abstract from the med-
ical records information that is generally included in the
hand physical examination at the time of enrollment. The
hand physical included measurements of patient height,
weight, dominant hand, 2-point discrimination (meas-
ured at digits #2 and #5), wrist width and thickness (for
MRI correlation), 2-point pinch strength (average of three
efforts), Semmes-Weinstein monofilament test (from
1.65 to 6.65), Tinel sign, Phalen sign (held greater than 1
minute), and flick test. Not every site routinely completed
all sensibility and/or strength tests.
Mackinnon-Dellon disk-criminators™ are used to test the
static two-point discrimination at the second and fifth
digits as a measure of sensibility to correlate to the MRI
findings. We tested each digit a minimum of three times
and until the tester was confident that a clear endpoint
was reached. The test was performed on both hands even
in patients with unilateral disease. The disk prongs are
held perpendicular to the long axis of the finger. The
prongs are placed upon the skin only with sufficient pres-
sure for a patient to determine that he is being stimulated.
The three-point pinch strength is tested bilaterally, with
the non-study hand being first. We recorded the mean of
three serial efforts of the key pinch measurement (thumb
pad to lateral aspect of middle phalanx of the index fin-
ger) using a B&L Engineered (B&L Engineering 3002 Dow
Ave, Suite 416, Tuscin CA 92780) 30 lbs. pinch gauge cal-
ibrated to +/- 1% accuracy.
Tinel sign is positive if tapping over the median nerve at
the distal wrist crease for approximately 10 seconds repro-
duces the pain, numbness and or tingling in the patients
hand or wrist. Phalen sign is positive if while holding
both wrists flexed at 90 degrees with the dorsum of the
hands in opposition to each other for a minimum of 1
minute produces dysesthesias and pain. A flick test is pos-
itive if in their response to being asked "What do you actu-
ally do with your hand(s) when your symptoms are at
their worst?" a patients gestures by flicking the wrist(s)
[66-74].
All subjects who enter the study undergo wrist MRI except
for subjects who have MRI contraindications (e.g., metal-
lic hardware within their body), are claustrophobic, who
exceed the weight limit of the MRI table, who have sched-
uling difficulties, or refuse the MRI. We use phased-array
Table 2: Imaging Parameters
T1- Weighted Axial T2-Weighted Axial
Description Spin Echo STIR
flip angle 90 90
Echo train length 6
TE Minimum/full 54
TR 450 3850
TI 160
Receiver bandwidth 16 12.8
Field of view 11 11
slice/skip 4/1 4/1
Saturation pulses Superior/inferior Superior/inferior
freq/phase matrix 256 × 256 256 × 224
freq direction Right/left Right/left
Number of excitations 2 2
Time 5:33 5:16
# images 20 11BMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
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surface coils to obtain high resolution images of the carpal
tunnel and median nerve. The imaging protocol consists
of a fast T1-weighted gradient echo coronal localizer, an
axial T1-weighted series and a short-tau inversion recovery
(STIR) T2-weighted series. This protocol has established
reliability and, because of the short imaging times,
patients usually are in the MR scanner for only 15–20
minutes. Imaging parameters for the axial series are listed
in table 2.
The MRI is interpreted by a neuroradiologist without
knowledge of the demographic data, clinical findings, or
electrodiagnostic study findings. The key imaging varia-
bles are the degree and length of signal abnormality
within the median nerve, flattening or swelling of the
median nerve, although other qualitative and quantitative
measurements will be made as well (table 3).
Patients receive a follow-up interview via telephone at 3,
6, 9 and 12 months. Hand specific symptom and func-
tional disability scores, along with general health and psy-
chological instruments are collected. For each interview,
we attempt to contact participants a minimum of three
times, varying the day and time of the call. In instances
where we are unable to reach a person by phone, the sur-
vey instruments are mailed along with a postage paid
return envelope. Some patients also consent to allow us to
contact them for follow-up using e-mail.
All data are collected onto hardcopies and entered into an
MS Access database using a web-based data entry system
that requires double entry of data to reduce errors in tran-
scribing. Error reporting to identify out of range answers,
inconsistent replies and compliance monitoring is rou-
tinely performed.
We developed stopping rules using CTSAQ symptom
scores, disability reporting, adverse event rates and rates of
"red flag" answers to a question asking about thoughts of
suicide on the SCL-90. A safety officer monitors these var-
iables for group differences, and also monitors response
variables, missing data, and protocol compliance.
A formal evaluation of efficacy will be conducted after 100
patients have been randomized to test for group
differences in the CTSAQ symptom severity score. We
adopted O'Brien-Fleming boundaries for discontinua-
tion, and therefore maintain an overall type I error rate of
5%. Additional stopping criteria include a suicidal idea-
tion rate difference of 10%, a difference in the change
from baseline rate of functional disability (as measured by
the CTSAQ function scale) of 20%, or a difference in the
number of days lost from work of 20%. The nature and
severity of the adverse events will also be considered indi-
vidually by the safety officer. Finally, individual item
response rates on all answered questionnaires with less
than 20% being incomplete, failure to collect greater than
75% at three-month follow-up, or enrollment rates below
the expected rate by more than 25% provided grounds for
the safety officer to recommend changes or stop the study.
In the primary analysis the CTSAQ functional score at 12
months will be compared between the surgical and non-
surgical treatment arms, using conventional t-tests and
ANCOVA techniques to adjust for baseline values. The
analysis will be conducted on an intention-to-treat basis.
Secondary analyses will include a comparison of second-
ary outcome measures (CTSAQ symptom severity, the SF-
36 scales, time lost from work) for the two treatment
arms. Adjusted analyses of CTSAQ functional status and
secondary outcomes at 1 year will be conducted using lin-
ear regression methods. To characterize the time evolu-
tion in the primary and secondary outcomes we will use
linear mixed models (or Generalized Estimating Equa-
tions in the case of categorical variables) to analyze the
repeated measures obtained at all follow-up visits. Finally,
we will use exploratory regression methods to determine
if baseline disability, psychological factors, MRI variables,
and electrodiagnostic measures correlate with clinical
outcomes.
We will use aggregate results of patient outcomes on the
CTSAQ and SF-36 scores to perform a descriptive analysis,
uncontrolled for other baseline factors. We will explore
factors that predict improvement in CTSAQ (symptom
score and functional status) and general health scores as
measured by the SF-36. Specific analysis and tests used
will depend on the distribution of the tested values. We
will also test the independent associations of the various
mental health domains, the work-related risk factors, and
physical findings to changes in the CTSAQ. Finally, we
will use linear regression to test relevant associations
while controlling for baseline demographics, co-morbid-
ity and other important variables to identify factors that
may predict improved outcomes at 1 year.
Table 3: Key MRI Imaging Variables
Median nerve
Signal (degree and length of signal abnormality)
Configuration (flattening or swelling)
Fascicular pattern
Flexor retinaculum bowing
Flexor tendon sheath interspacesBMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
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As important sub-analyses we will also determine the reli-
ability of quantitative MR median nerve measurements,
determine the correlation of symptoms and function in
patients with these quantitative MR measurements as well
as with electrodiagnostic studies (EDS), and construct a
cost-effectiveness model to test the hypothesis that MRI is
an efficient method for selecting patients with mild or
moderate CTS who are likely to benefit from surgery.
The prospective cohort study by Katz et al. provided data
on outcome differences between surgical and non-surgical
patients [75]. They also used the CTSAQ as an outcome
measure and found a 23–45% difference between surgical
and non-surgical groups. Using pilot data we have calcu-
lated the mean reduction in CTSAQ function scores for 74
non-surgical patients as m0 = 0.264 (standard deviation =
0.670) and the mean reduction for 30 surgical patients as
m1 = 0.818 (standard deviation = 1.033). The observed
effect of surgery is m1 - m0 = 0.818-0.264 = 0.554 point
greater reduction. We used the pilot data estimates of var-
iance to calculate the sample size required to obtain suffi-
cient power (80% or 90%) for various differences in
means (m1-m0).
If we consider the difference in means observed for the
pilot data (m1-m0 = 0.554) then 48+48 = 96 subjects are
adequate for 80% power and a total of 64+64 = 128 are
required for 90% power (refer to following table). How-
ever, since we are recruiting patients with less severe dis-
ease, we would expect smaller improvements in the scores
from baseline to follow-up and hence, smaller effect sizes.
Thus, it is reasonable to power the study to detect a differ-
ence in means of 0.4 rather than 0.5. Since our primary
analysis will use the more efficient ANCOVA, these sam-
ple size estimates based on observed change scores (post-
pre) are slightly conservative. This should allow for a
small percentage of subjects lost to follow-up. Similar
power calculations were conducted to assess the power to
detect an impact on CTSAQ symptom scores. The pilot
data suggest a 0.67 point greater reduction in symptoms
for the surgical patients, and variance estimates lead to
sample sizes of 30+30 = 60 total patients, and 40+40 = 80
total patients to detect 0.67 point difference (table 4). Our
study will aim to enroll 100 patients into each arm of the
study and this will be sufficient to detect the smallest clin-
ically relevant differences.
Discussion
An RCT offers the best chance of answering, in an unbi-
ased fashion, the relative efficacies of surgery compared
with conservative therapy for patients with mild to mod-
erate CTS. Our study is designed to test two main hypoth-
eses: 1) that patients with mild or moderate CTS benefit
from surgery more than conservative therapy, and; 2) that
high-resolution wrist MRI accurately identifies which
patients with mild to moderate symptoms are more likely
to benefit from surgery. We expect our findings to be more
generalizable to the primary care clinicians and include
milder cases of CTS than Gerritsens' study. No previous
study has sufficiently considered conservative treatment
options of vitamin B6, ultrasound, anti-inflammatory
drugs, and hand exercises in combination versus surgical
treatment. Furthermore, our study offers the unique use of
wrist MRI data to establish the diagnostic and predictive
understanding of carpal tunnel syndrome.
Acknowledgements
The study is funded by the National Institute of Arthritis and Musculoskel-
etal Skin Disease (NIAMS) (P60 AR48093) and is conducted by the Univer-
sity of Washington's Multidisciplinary Clinical Research Center, located in 
Seattle, Washington, U.S.A.
References
1. Cheadle A, Franklin G, Wolfhagen C, Savarino J, Liu PY, Salley C,
Weaver M: Factors influencing the duration of work-related
disability: a population-based study of Washington State
workers' compensation. Am J Public Health 1994, 84:190-196.
2. Feuerstein M, Burrell LM, Miller VI, Lincoln A, Huang GD, Berger R:
Clinical management of carpal tunnel syndrome: a 12-year
review of outcomes. Am J Ind Med 1999, 35:232-245.
3. Katz JN, Simmons BP: Clinical practice. Carpal tunnel
syndrome. N Engl J Med 2002, 346:1807-1812.
4. Katz RT: Carpal tunnel syndrome: a practical review. Am Fam
Physician 1994, 49:1371-9, 1385-6.
5. Sen D, Chhaya S, Morris VH: Carpal tunnel syndrome. Hosp Med
2002, 63:392-395.
6. Verdugo RJ, Salinas RS, Castillo J, Cea JG: Surgical versus non-sur-
gical treatment for carpal tunnel syndrome. Cochrane Database
Syst Rev 2002:CD001552.
7. Garland H, Langworth EP, Taverner D, Clark JM: Surgical Treat-
ment for the Carpal Tunnel Syndrome.  Lancet 1964,
13:1129-1130.
8. Gerritsen AA, de Vet HC, Scholten RJ, Bertelsmann FW, de Krom
MC, Bouter LM: Splinting vs surgery in the treatment of carpal
tunnel syndrome: a randomized controlled trial. Jama 2002,
288:1245-1251.
9. Gerritsen AA, Scholten RJ, Assendelft WJ, Kuiper H, de Vet HC,
Bouter LM: Splinting or surgery for carpal tunnel syndrome?
Design of a randomized controlled trial [ISRCTN18853827].
BMC Neurol 2001, 1:8.
10. Gerritsen AA, de Krom MC, Struijs MA, Scholten RJ, de Vet HC,
Bouter LM: Conservative treatment options for carpal tunnel
syndrome: a systematic review of randomised controlled
trials. J Neurol 2002, 249:272-280.
11. Bonebrake AR, Fernandez JE, Dahalan JB, Marley RJ: A treatment
for carpal tunnel syndrome: results of a follow-up study. J
Manipulative Physiol Ther 1993, 16:125-139.
Table 4: Power calculation In order to have 80% or 90% power 
for the analysis of reduction in function scores (change) we 
would need (per study arm)
m1-m0
0.20 0.30 0.40 0.50
80% power 298 133 75 48
90% power 399 177 100 64BMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
Page 8 of 9
(page number not for citation purposes)
12. Davis PT, Hulbert JR: Carpal tunnel syndrome: conservative
and nonconservative treatment. A chiropractic physician's
perspective. J Manipulative Physiol Ther 1998, 21:356-362.
13. Davis PT, Hulbert JR, Kassak KM, Meyer JJ: Comparative efficacy
of conservative medical and chiropractic treatments for car-
pal tunnel syndrome: a randomized clinical trail. J Manipulative
Physiol Ther 1998, 21:317-326.
14. Rozmaryn LM, Dovelle S, Rothman ER, Gorman K, Olvey KM, Bartko
JJ: Nerve and tendon gliding exercises and the conservative
management of carpal tunnel syndrome. J Hand Ther 1998,
11:171-179.
15. Garfinkel MS, Singhal A, Katz WA, Allan DA, Reshetar R, Schumacher
HRJ: Yoga-based intervention for carpal tunnel syndrome: a
randomized trial. Jama 1998, 280:1601-1603.
16. Celiker R, Arslan S, Inanici F: Corticosteroid injection vs. nons-
teroidal antiinflammatory drug and splinting in carpal tunnel
syndrome. Am J Phys Med Rehabil 2002, 81:182-186.
17. Harrast M, Kraft G: Yoga for carpal tunnel syndrome. Jama 1999,
281:2088.
18. Sequeira W: Yoga in treatment of carpal-tunnel syndrome.
Lancet 1999, 353:689-690.
19. Wong SM, Hui AC, Tang A, Ho PC, Hung LK, Wong KS, Kay R, Li E:
Local vs systemic corticosteroids in the treatment of carpal
tunnel syndrome. Neurology 2001, 56:1565-1567.
20. Ozdogan H, Yazici H: The efficacy of local steroid injections in
idiopathic carpal tunnel syndrome: a double-blind study. Br J
Rheumatol 1984, 23:272-275.
21. Girlanda P, Dattola R, Venuto C, Mangiapane R, Nicolosi C, Messina
C: Local steroid treatment in idiopathic carpal tunnel syn-
drome: short- and long-term efficacy.  J Neurol 1993,
240:187-190.
22. Dammers JW, Veering MM, Vermeulen M: Injection with methyl-
prednisolone proximal to the carpal tunnel: randomised
double blind trial. Bmj 1999, 319:884-886.
23. Herskovitz S, Berger AR, Lipton RB: Low-dose, short-term oral
prednisone in the treatment of carpal tunnel syndrome. Neu-
rology 1995, 45:1923-1925.
24. Chang MH, Chiang HT, Lee SS, Ger LP, Lo YK: Oral drug of choice
in carpal tunnel syndrome. Neurology 1998, 51:390-393.
25. Chang MH, Ger LP, Hsieh PF, Huang SY: A randomised clinical
trial of oral steroids in the treatment of carpal tunnel syn-
drome: a long term follow up. J Neurol Neurosurg Psychiatry 2002,
73:710-714.
26. Ebenbichler GR, Resch KL, Nicolakis P, Wiesinger GF, Uhl F, Ghanem
AH, Fialka V: Ultrasound treatment for treating the carpal
tunnel syndrome: randomised "sham" controlled trial. Bmj
1998, 316:731-735.
27. Ellis J, Folkers K, Watanabe T, Kaji M, Saji S, Caldwell JW, Temple CA,
Wood FS: Clinical results of a cross-over treatment with pyri-
doxine and placebo of the carpal tunnel syndrome. Am J Clin
Nutr 1979, 32:2040-2046.
28. Ellis JM, Azuma J, Watanabe T, Fokers K, Lowell JR, Hurst GA, Ho
Ahn C, Shuford EHJ, Ulrich RF: Survey and new data on treat-
ment with pyridoxine of patients having a clinical syndrome
including the carpal tunnel and other defects. Res Commun
Chem Pathol Pharmacol 1977, 17:165-177.
29. Ellis JM, Folkers K, Levy M, Shizukuishi S, Lewandowski J, Nishii S,
Schubert HA, Ulrich R: Response of vitamin B-6 deficiency and
the carpal tunnel syndrome to pyridoxine. Proc Natl Acad Sci U
S A 1982, 79:7494-7498.
30. Ellis JM, Folkers K, Minadeo M, VanBuskirk R, Xia LJ, Tamagawa H: A
deficiency of vitamin B6 is a plausible molecular basis of the
retinopathy of patients with diabetes mellitus. Biochem Biophys
Res Commun 1991, 179:615-619.
31. Ellis JM, Kishi T, Azuma J, Folkers K: Vitamin B6 deficiency in
patients with a clinical syndrome including the carpal tunnel
defect. Biochemical and clinical response to therapy with
pyridoxine. Res Commun Chem Pathol Pharmacol 1976, 13:743-757.
32. Stransky M, Rubin A, Lava NS, Lazaro RP: Treatment of carpal
tunnel syndrome with vitamin B6: a double-blind study. South
Med J 1989, 82:841-842.
33. Stevens JC, Sun S, Beard CM, O'Fallon WM, Kurland LT: Carpal tun-
nel syndrome in Rochester, Minnesota, 1961 to 1980. Neurol-
ogy 1988, 38:134-138.
34. Campion D: Electrodiagnostic testing in hand surgery. J Hand
Surg [Am] 1996, 21:947-956.
35. Cho DS, Cho MJ: The electrodiagnosis of the carpal tunnel
syndrome. S D J Med 1989, 42:5-8.
36. Concannon MJ, Gainor B, Petroski GF, Puckett CL: The predictive
value of electrodiagnostic studies in carpal tunnel syndrome.
Plast Reconstr Surg 1997, 100:1452-1458.
37. Finestone HM, Woodbury GM, Collavini T, Marchuk Y, Maryniak O:
Severe carpal tunnel syndrome: clinical and electrodiagnos-
tic outcome of surgical and conservative treatment. Muscle
Nerve 1996, 19:237-239.
38. Glowacki KA, Breen CJ, Sachar K, Weiss AP: Electrodiagnostic
testing and carpal tunnel release outcome. J Hand Surg [Am]
1996, 21:117-121.
39. Rempel D, Evanoff B, Amadio PC, de Krom M, Franklin G, Franzblau
A, Gray R, Gerr F, Hagberg M, Hales T, Katz JN, Pransky G: Consen-
sus criteria for the classification of carpal tunnel syndrome in
epidemiologic studies. Am J Public Health 1998, 88:1447-1451.
40. Nathan PA, Keniston RC, Meadows KD, Lockwood RS: The rela-
tionship between body mass index and the diagnosis of car-
pal tunnel syndrome. Muscle Nerve 1994, 17:1491-1493.
41. Filler AG, Kliot M, Howe FA, Hayes CE, Saunders DE, Goodkin R, Bell
BA, Winn HR, Griffiths JR, Tsuruda JS: Application of magnetic
resonance neurography in the evaluation of patients with
peripheral nerve pathology. J Neurosurg 1996, 85:299-309.
42. Jarvik JG, Kliot M, Maravilla KR: MR nerve imaging of the wrist
and hand. Hand Clin 2000, 16:13-24, vii.
43. Jarvik JG, Yuen E, Haynor DR, Bradley CM, Fulton-Kehoe D, Smith-
Weller T, Wu R, Kliot M, Kraft G, Wang L, Erlich V, Heagerty PJ,
Franklin GM: MR nerve imaging in a prospective cohort of
patients with suspected carpal tunnel syndrome.  Neurology
2002, 58:1597-1602.
44. Jarvik JG, Yuen E, Kliot M: Diagnosis of carpal tunnel syndrome:
electrodiagnostic and MR imaging evaluation.  Neuroimaging
Clin N Am 2004, 14:93-102, viii.
45. Lew HL, Wang L, Robinson LR: Test-retest reliability of com-
bined sensory index: implications for diagnosing carpal tun-
nel syndrome. Muscle Nerve 2000, 23:1261-1264.
46. Robinson LR, Micklesen PJ, Wang L: Strategies for analyzing
nerve conduction data: superiority of a summary index over
single tests. Muscle Nerve 1998, 21:1166-1171.
47. Katz JN, Stirrat CR: A self-administered hand diagram for the
diagnosis of carpal tunnel syndrome. J Hand Surg [Am] 1990,
15:360-363.
48. Katz JN, Stirrat CR, Larson MG, Fossel AH, Eaton HM, Liang MH: A
self-administered hand symptom diagram for the diagnosis
and epidemiologic study of carpal tunnel syndrome.  J
Rheumatol 1990, 17:1495-1498.
49. Bessette L, Keller RB, Lew RA, Simmons BP, Fossel AH, Mooney N,
Katz JN: Prognostic value of a hand symptom diagram in sur-
gery for carpal tunnel syndrome. J Rheumatol 1997, 24:726-734.
50. Levine DW, Simmons BP, Koris MJ, Daltroy LH, Hohl GG, Fossel AH,
Katz JN: A self-administered questionnaire for the assess-
ment of severity of symptoms and functional status in carpal
tunnel syndrome. J Bone Joint Surg Am 1993, 75:1585-1592.
51. Bessette L, Sangha O, Kuntz KM, Keller RB, Lew RA, Fossel AH, Katz
JN: Comparative responsiveness of generic versus disease-
specific and weighted versus unweighted health status meas-
ures in carpal tunnel syndrome. Med Care 1998, 36:491-502.
52. Atroshi I, Breidenbach WC, McCabe SJ: Assessment of the carpal
tunnel outcome instrument in patients with nerve-compres-
sion symptoms. J Hand Surg [Am] 1997, 22:222-227.
53. Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychi-
atric rating scale--preliminary report.  Psychopharmacol Bull
1973, 9:13-28.
54. Derogatis LR, Lipman RS, Covi L, Rickels K: Factorial invariance of
symptom dimensions in anxious and depressive neuroses.
Arch Gen Psychiatry 1972, 27:659-665.
55. Derogatis LR, Rickels K, Rock AF: The SCL-90 and the MMPI: a
step in the validation of a new self-report scale. Br J Psychiatry
1976, 128:280-289.
56. Flor H, Behle DJ, Birbaumer N: Assessment of pain-related cog-
nitions in chronic pain patients. Behav Res Ther 1993, 31:63-73.
57. Michael ES, Burns JW: Catastrophizing and pain sensitivity
among chronic pain patients: moderating effects of sensory
and affect focus. Ann Behav Med 2004, 27:185-194.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Musculoskeletal Disorders 2005, 6:2 http://www.biomedcentral.com/1471-2474/6/2
Page 9 of 9
(page number not for citation purposes)
58. Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E:
Factor structure, reliability, and validity of the Pain Cata-
strophizing Scale. J Behav Med 1997, 20:589-605.
59. Sullivan MJ, Stanish W, Waite H, Sullivan M, Tripp DA: Catastro-
phizing, pain, and disability in patients with soft-tissue
injuries. Pain 1998, 77:253-260.
60. Turner JA, Jensen MP, Warms CA, Cardenas DD: Catastrophizing
is associated with pain intensity, psychological distress, and
pain-related disability among individuals with chronic pain
after spinal cord injury. Pain 2002, 98:127-134.
61. Reinert DF, Allen JP: The Alcohol Use Disorders Identification
Test (AUDIT): a review of recent research. Alcohol Clin Exp Res
2002, 26:272-279.
62. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M: Devel-
opment of the Alcohol Use Disorders Identification Test
(AUDIT): WHO Collaborative Project on Early Detection of
Persons with Harmful Alcohol Consumption--II.  Addiction
1993, 88:791-804.
63. Volk RJ, Steinbauer JR, Cantor SB, Holzer CE: The Alcohol Use
Disorders Identification Test (AUDIT) as a screen for at-risk
drinking in primary care patients of different racial/ethnic
backgrounds. Addiction 1997, 92:197-206.
64. Bruske J, Bednarski M, Grzelec H, Zyluk A: The usefulness of the
Phalen test and the Hoffmann-Tinel sign in the diagnosis of
carpal tunnel syndrome. Acta Orthop Belg 2002, 68:141-145.
65. Kanaan N, Sawaya RA: Carpal tunnel syndrome: modern diag-
nostic and management techniques.  Br J Gen Pract 2001,
51:311-314.
66. MacDermid JC, Wessel J: Clinical diagnosis of carpal tunnel syn-
drome: a systematic review. J Hand Ther 2004, 17:309-319.
67. Marx RG, Hudak PL, Bombardier C, Graham B, Goldsmith C, Wright
JG: The reliability of physical examination for carpal tunnel
syndrome. J Hand Surg [Br] 1998, 23:499-502.
68. Pryse-Phillips WE: Validation of a diagnostic sign in carpal tun-
nel syndrome. J Neurol Neurosurg Psychiatry 1984, 47:870-872.
69. Salerno DF, Franzblau A, Werner RA, Chung KC, Schultz JS, Becker
MP, Armstrong TJ: Reliability of physical examination of the
upper extremity among keyboard operators. Am J Ind Med
2000, 37:423-430.
70. Szabo RM, Slater RRJ, Farver TB, Stanton DB, Sharman WK: The
value of diagnostic testing in carpal tunnel syndrome. J Hand
Surg [Am] 1999, 24:704-714.
71. Phalen GS: Reflections on 21 years' experience with the car-
pal-tunnel syndrome. Jama 1970, 212:1365-1367.
72. Vargas Busquets MA: Historical commentary: the wrist flexion
test (Phalen sign). J Hand Surg [Am] 1994, 19:521.
73. Katz JN, Keller RB, Fossel AH, Punnett L, Bessette L, Simmons BP,
Mooney N: Predictors of return to work following carpal tun-
nel release. Am J Ind Med 1997, 31:85-91.
74. Katz JN, Keller RB, Simmons BP, Rogers WD, Bessette L, Fossel AH,
Mooney NA: Maine Carpal Tunnel Study: outcomes of opera-
tive and nonoperative therapy for carpal tunnel syndrome in
a community-based cohort. J Hand Surg [Am] 1998, 23:697-710.
75. Katz JN, Losina E, Amick BC, Fossel AH, Bessette L, Keller RB: Pre-
dictors of outcomes of carpal tunnel release. Arthritis Rheum
2001, 44:1184-1193.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/6/2/prepub